ATE280583T1 - Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form - Google Patents

Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form

Info

Publication number
ATE280583T1
ATE280583T1 AT00940916T AT00940916T ATE280583T1 AT E280583 T1 ATE280583 T1 AT E280583T1 AT 00940916 T AT00940916 T AT 00940916T AT 00940916 T AT00940916 T AT 00940916T AT E280583 T1 ATE280583 T1 AT E280583T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
lyophilized form
stabilized pharmaceutical
stabilized
lyophilized
Prior art date
Application number
AT00940916T
Other languages
English (en)
Inventor
Seiji Sawai
Akihiro Kasai
Kazumi Ohtomo
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE280583(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE280583T1 publication Critical patent/ATE280583T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00940916T 1999-07-01 2000-06-29 Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form ATE280583T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01
PCT/JP2000/004381 WO2001002002A1 (en) 1999-07-01 2000-06-29 Stabilized pharmaceutical composition in lyophilized form

Publications (1)

Publication Number Publication Date
ATE280583T1 true ATE280583T1 (de) 2004-11-15

Family

ID=16210881

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00940916T ATE280583T1 (de) 1999-07-01 2000-06-29 Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form

Country Status (28)

Country Link
US (2) US6774104B1 (de)
EP (1) EP1107777B1 (de)
JP (2) JP3381722B2 (de)
KR (1) KR100454784B1 (de)
CN (2) CN100352495C (de)
AR (1) AR024634A1 (de)
AT (1) ATE280583T1 (de)
AU (1) AU752265B2 (de)
BR (2) BRPI0006823B8 (de)
CA (1) CA2341568C (de)
CZ (1) CZ295720B6 (de)
DE (1) DE60015279T2 (de)
ES (1) ES2225161T3 (de)
HK (2) HK1040057B (de)
HU (1) HU229089B1 (de)
ID (1) ID29468A (de)
IL (2) IL141455A0 (de)
MX (1) MXPA01000601A (de)
NO (1) NO330353B1 (de)
NZ (1) NZ510290A (de)
OA (1) OA11601A (de)
PL (1) PL200141B1 (de)
PT (1) PT1107777E (de)
RU (1) RU2251411C2 (de)
TR (1) TR200100609T1 (de)
TW (1) TWI233805B (de)
WO (1) WO2001002002A1 (de)
ZA (1) ZA200101589B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
EP1525884B1 (de) * 2002-07-31 2011-10-12 Senju Pharmaceutical Co., Ltd. Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20050130909A1 (en) * 2002-11-18 2005-06-16 Luigi Colombo Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
JPWO2005084679A1 (ja) * 2004-03-04 2007-11-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンズアミジン誘導体含有組成物及びベンズアミジン誘導体の安定化方法
EP1751150A2 (de) * 2004-05-19 2007-02-14 Neurosearch A/S Neue azabicyclische arylderivate
US20090169566A1 (en) * 2004-11-22 2009-07-02 Anadis Ltd. Bioactive compositions
KR101307999B1 (ko) * 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
WO2007010995A1 (ja) * 2005-07-20 2007-01-25 Kyowa Medex Co., Ltd. 生体試料中のペプチドの安定化方法
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
US20150148338A1 (en) * 2012-05-22 2015-05-28 Paion Uk Limited Compositions comprising short-acting benzodiazepines
EP3100732A1 (de) 2013-03-15 2016-12-07 Merck Sharp & Dohme Corp. Antibiotische ceftolozanzusammensetzungen
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
KR102294405B1 (ko) * 2013-06-05 2021-08-25 더 유니버시티 오브 브리티쉬 콜롬비아 항-섬유형성 화합물, 방법 및 이의 용도
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
EP3150621A4 (de) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Zusammensetzung einer cyclischen peptidverbindung, herstellungsverfahren dafür und verwendungen davon
US10294224B2 (en) * 2014-12-05 2019-05-21 Meiji Seika Pharma Co., Ltd. Lyophilized composition of a diazabicyclooctane compound and process of producing the same
EP3240529B1 (de) * 2014-12-31 2022-02-02 Galenicum Health S.L.U. Stabile pharmazeutische zusammensetzungen mit micafungin
PL3058958T3 (pl) 2015-02-23 2019-02-28 Selectchemie Ag Kompozycja anidulafunginy
FI3554474T3 (fi) 2016-12-16 2024-02-21 Baxter Int Mikafungiinikoostumuksia
WO2019005829A1 (en) * 2017-06-26 2019-01-03 Wayne State University METHODS AND COMPOSITIONS RELATING TO CANCER DEPENDENT ON HORMONE RECEPTORS
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (de) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stabile pharmazeutische injizierbare zusammensetzungen von micafungin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
FI912873A (fi) * 1990-06-18 1991-12-19 Fujisawa Pharmaceutical Co Ny polypeptidfoerening och foerfarande foer dess framstaellning.
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
AU681119B2 (en) * 1993-05-17 1997-08-21 Fujisawa Pharmaceutical Co., Ltd. New polypeptide compound and a process for preparation thereof
DK0788511T3 (da) * 1994-10-07 2003-03-31 Fujisawa Pharmaceutical Co Cykliske hexapeptider med antibiotisk aktivitet
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
EP1854877B1 (de) * 1996-03-08 2012-02-08 Astellas Pharma Inc. Verfahren zur Deacylierung von zyklischen Lipopeptiden
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
ES2433678T3 (es) * 1999-03-03 2013-12-12 Eli Lilly & Company Formulaciones farmacéuticas de equinocandina que contienen tensioactivos formadores de micelas
BR0008713A (pt) * 1999-03-03 2001-12-26 Lilly Co Eli Processos para preparar formulações ecomposições farmacêuticas orais com ecb
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
IL141455A0 (en) 2002-03-10
HK1080724A1 (en) 2006-05-04
CN1636591A (zh) 2005-07-13
ES2225161T3 (es) 2005-03-16
IL141455A (en) 2006-12-31
CA2341568A1 (en) 2001-01-11
OA11601A (en) 2004-07-30
ID29468A (id) 2001-08-30
BRPI0006823B1 (pt) 2020-01-07
EP1107777A1 (de) 2001-06-20
HUP0103740A2 (hu) 2002-02-28
AU752265B2 (en) 2002-09-12
NO330353B1 (no) 2011-04-04
HUP0103740A3 (en) 2002-08-28
PT1107777E (pt) 2005-01-31
CN1315865A (zh) 2001-10-03
JP2002363097A (ja) 2002-12-18
NZ510290A (en) 2003-07-25
HK1040057A1 (en) 2002-05-24
DE60015279D1 (de) 2004-12-02
KR20010072903A (ko) 2001-07-31
ZA200101589B (en) 2002-09-02
WO2001002002A1 (en) 2001-01-11
US7112565B2 (en) 2006-09-26
AR024634A1 (es) 2002-10-16
RU2251411C2 (ru) 2005-05-10
PL346297A1 (en) 2002-01-28
DE60015279T2 (de) 2005-05-25
MXPA01000601A (es) 2002-04-08
HK1040057B (zh) 2005-08-05
CZ295720B6 (cs) 2005-10-12
AU5572200A (en) 2001-01-22
TWI233805B (en) 2005-06-11
CN100352495C (zh) 2007-12-05
TR200100609T1 (tr) 2001-07-23
CA2341568C (en) 2011-10-25
JP3381722B2 (ja) 2003-03-04
NO20010893L (no) 2001-04-24
CZ20011186A3 (cs) 2001-09-12
EP1107777B1 (de) 2004-10-27
US6774104B1 (en) 2004-08-10
HU229089B1 (en) 2013-07-29
KR100454784B1 (ko) 2004-11-05
US20040157769A1 (en) 2004-08-12
BR0006823A (pt) 2001-06-05
BRPI0006823B8 (pt) 2021-05-25
CN1179748C (zh) 2004-12-15
JP2003503462A (ja) 2003-01-28
JP4691866B2 (ja) 2011-06-01
NO20010893D0 (no) 2001-02-22
PL200141B1 (pl) 2008-12-31

Similar Documents

Publication Publication Date Title
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
ATE468324T1 (de) Pharmazeutische zusammensetzung
NO20015175L (no) Farmasöytisk sammensetning
DE60029115D1 (de) Antigen enthaltende pharmazeutische zusammensetzung
DE60118008D1 (de) Pharmazeutische zusammensetzungen mit amlodipinmaleat
ATE279961T1 (de) Neue pharmazeutische zusammensetzung
DE69924999D1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
ATE404180T1 (de) Geschmacksmaskierte pharmazeutische partikel
DE60110372D1 (de) Pharmazeutische zusammensetzungen mit botulinum toxin
ID27415A (id) Komposisi farmaseutik
ATE295081T1 (de) Hilfsstoff-zusammensetzung
DE59915033D1 (de) Pharmazeutische Zubereitung
ID29262A (id) Komposisi farmasi
ID27201A (id) Komposisi farmasi
DE59910298D1 (de) Pharmazeutische levothyroxinzubereitung
NO20032614D0 (no) Farmasöytisk sammensetning med forbedret absorbabilitet
DE60129238D1 (de) Pharmazeutische zusammensetzung
DE10084344T1 (de) Cyclosporin enthaltende pharmazeutische Zusammensetzung
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
ATE295150T1 (de) Pharmazeutische zusammensetzungen
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
FI4488U1 (fi) Farmaseuttinen koostumus
DE60136367D1 (de) Pharmazeutische zusammensetzung mit modifiziertem träger
ID26215A (id) Komposisi farmasi
DE10291905D2 (de) Pharmazeutische Zusammensetzung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1107777

Country of ref document: EP